Items Tagged ‘kisqali’

February 13, 2018

Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer

By

CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. Results from […]

View full entry

Tags: Breast Cancer, CDK4/6 inhibitor, kisqali, News, ribociclib, treatment


December 12, 2017

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2017 Annual San Antonio Breast Cancer […]

View full entry

Tags: advanced breast cancer, Breast Cancer, cyclin-dependent kinase, inhibitor, kisqali, MONELESSA 7, News, Precision Cancer Medicine, premenopausal, ribociclib, San Antonio Breast Cancer Symposium


November 14, 2017

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their older counterparts, researchers however have more recently begun to focus on improving the treatment outcomes for […]

View full entry

Tags: advanced breast cancer, Breast Cancer, CDK4/6, cyclin-dependent kinase 4 and 6, kisqali, MONALEESA-7, News, Precision Cancer Medicine, ribociclib